Regulation of ELL2 stability and polyubiquitination by EAF2 in prostate cancer cells. Issue 15 (15th July 2018)

• Record Type: Journal Article
• Authors: Yang, Tiejun; Jing, Yifeng; Dong, Jun; Yu, Xinpei; Zhong, Mingming; Pascal, Laura E.; Wang, Dan; Zhang, Zhongxian; Qiao, Baoping; Wang, Zhou
• Is Part Of: Prostate. Volume 78:Issue 15(2018)
• Page Start: 1201
• Page End: 1212
• Publication Date: 2018-07-15
• Subjects: EAF2 -- ELL2 -- polyubiquitination -- prostate cancer; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.23695
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract : Background: Elongation factor for RNA polymerase 2 (ELL2) and ELL associated factor 2 (EAF2) have been reported to have tumor suppressive properties in prostate epithelial cells. Aims: We investigated ELL2 expression in human prostate cancer specimens, and ELL2 protein stability and ubiquitination in prostate cancer cells. Materials and Methods: Immunostaining analysis of human prostate cancer specimens was used to determine ELL2 expression in tumor and normal tissues. ELL2 knockdown in prostate cancer cell lines LNCaP and C4‐2 was used to compare proliferation and motility. Deletion and site‐directed mutagenesis was used to identify amino acid residues in ELL2 that were important for degradation. Results: ELL2 protein was downregulated in prostate cancer specimens and was up‐regulated by androgens in prostate cancer cell lines LNCaP and C4‐2. ELL2 knockdown enhanced prostate cancer cell proliferation and motility. ELL2 protein has a short half‐life and was stabilized by proteasome inhibitor MG132. Amino acid residues K584 and K599 in ELL2 were important for ELL2 degradation. EAF2 could stabilize ELL2 and inhibited its polyubiquitination. Conclusion: Our findings provide further evidence that ELL2 is a potential tumor suppressor frequently down‐regulated in clinical prostate cancer specimens and provides new insights into regulation of ELL2 protein level by polyubiquitination and EAF2 binding.